Advertised drug (n advertisements) | Brand name | EMA authorisationa | Marketing holderb |
---|---|---|---|
Drug groups | |||
Beta2-agonist + steroid inhalations (28) | |||
Vilanterol + fluticasone furoate (11) | Relvar Ellipta | Nov 2013 | GlaxoSmithKline |
Formoterol + budesonide (9) | DuoResp Spiromax | April 2014 | Teva Pharma |
Formoterol + fluticasone propionate (8) | Flutiform | June 2012 | Norpharma |
Beta2-agonist + anticholinergic agents (26) | |||
Olodaterol + tiotropium (18) | Spiolto Respimat | N/Ac | Boehringer Ingelheim |
Vilanterol + umeclidinium (5) | Anoro Ellipta | May 2014 | GlaxoSmithKline |
Formoterol + aclidinium bromide (3) | Duaklir Genuair | Nov 2014 | Astra Zeneca |
ADHD medications (16) | |||
Lisdexamfetamine (12) | Aduvanz | N/Ac | Shire Pharmaceuticals |
Atomoxetine (4) | Strattera | N/Ac | Eli Lilly |
New oral anticoagulants (6) | |||
Rivaroxaban (4) | Xarelto | June 2013 | Bayer |
Dabigatran (2) | Pradaxa | Aug 2011 | Boehringer Ingelheim |
Single drugs | |||
Paracetamol modified-release (15) | Panodil 665 | N/Ac | GlaxoSmithKline |
Vortioxetine (8) | Brintellix | Dec 2013 | Lundbeck |
Aripiprazole intramuscular depot (7) | Abilify Maintena | Nov 2013 | Otsuka/Lundbeck |
Pneumococcal vaccine (6) | Prevenar 13 | Jan 2010 | Pfizer |
Canagliflozin (6) | Invokana | Nov 2013 | Janssen-Cilag |